A Trial of Intratumoral Injections of SD-101 in Combination With Pembrolizumab in Patients With Metastatic Melanoma or Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Conditions:   Metastatic Melanoma;   Head Neck Cancer
Interventions:   Drug: SD-101;   Biological: Pembrolizumab;   Drug: SD-101;   Biological: Pembrolizumab
Sponsors:   Dynavax Technologies Corporation;   Merck Sharp & Dohme Corp.
Recruiting - verified January 2017

http://ift.tt/2kWtMo7